Spots Global Cancer Trial Database for nilotinib
Every month we try and update this database with for nilotinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | NCT01275196 | Chronic Myeloid... | Nilotinib Imatinib | 18 Years - | Novartis | |
| TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study | NCT01657604 | Chronic Myeloid... | Peginterferon α... Nilotinib | 18 Years - | University of Jena | |
| Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib | NCT02733445 | Chronic Myeloid... | dasatinib nilotinib | 18 Years - | Bristol-Myers Squibb | |
| Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) | NCT00129740 | Leukemia, Myelo... | Nilotinib | 16 Years - | M.D. Anderson Cancer Center | |
| Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01275586 | Neurofibromatos... NF1 Neurofibromas | Tasigna | 18 Years - | Indiana University | |
| Nilotinib in PH+, BCR-, ABL+ CML Patients | NCT01535391 | Chronic Myeloid... | Nilotinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | NCT05185947 | Gynecologic Can... Gynecologic Neo... Peritoneal Carc... Peritoneal Neop... Ovarian Cancer Ovarian Neoplas... Colorectal Canc... Colorectal Neop... Appendiceal Can... Appendiceal Neo... | Paclitaxel Nilotinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Nilotinib Pre and Post Allogeneic Stem Cell Transplantation | NCT00750659 | Chronic Myeloid... Acute Lymphobla... Stem Cell Trans... | Nilotinib | 18 Years - 65 Years | Sheba Medical Center | |
| Efficacy and Safety of Nilotinib in CML-CP | NCT03332511 | Chronic Myeloid... | Nilotinib | 19 Years - | Seoul National University Hospital | |
| Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | NCT02709083 | Chronic Myeloge... Chronic Myeloid... Leukemia | Dasatinib Imatinib Mesyla... Nilotinib | 17 Years - | Emory University | |
| Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) | NCT00782834 | Gastrointestina... | Nilotinib | 18 Years - | Fox Chase Cancer Center | |
| A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) | NCT01077544 | Chronic Myeloid... Acute Lymphobla... | Nilotinib | 1 Year - 17 Years | Novartis | |
| Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia | NCT00762632 | Acute Myeloid L... | NILOTINIB EVEROLIMUS | 18 Years - | Technical University of Munich | |
| Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) | NCT00129740 | Leukemia, Myelo... | Nilotinib | 16 Years - | M.D. Anderson Cancer Center | |
| Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors | NCT01751425 | Chronic Myeloge... Chronic Myeloge... Minimal Residua... Philadelphia Ch... | Dasatinib Imatinib Mesyla... Nilotinib Ruxolitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00905398 | Precursor B-Cel... Acute Lymphobla... | Nilotinib | 18 Years - 75 Years | Universidade Federal do Rio de Janeiro | |
| A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML | NCT02973711 | Leukemia, Chron... | Nilotinib Ruxolitinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT01528085 | Philadelphia Ch... | Nilotinib | 55 Years - | Goethe University | |
| Nilotinib, for Patients With CML-CP or CML-AP | NCT04518644 | Chronic Myeloge... | Nilotinib | 18 Years - 99 Years | Novartis | |
| TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study | NCT01657604 | Chronic Myeloid... | Peginterferon α... Nilotinib | 18 Years - | University of Jena | |
| KRT-232 and TKI Study in Chronic Myeloid Leukemia | NCT04835584 | Chronic Myeloid... | KRT-232 Dasatinib Nilotinib | 18 Years - | Kartos Therapeutics, Inc. | |
| Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients | NCT02253277 | Chronic Myeloid... | Nilotinib Ruxolitinib | 18 Years - | Novartis | |
| Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML | NCT01690065 | Chronic Myeloid... Untreated Adult... | Nilotinib+AD in... | 18 Years - 65 Years | Ulsan University Hospital | |
| Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults | NCT01884922 | Refractory Low-... Recurrent Low-g... | Nilotinib Vinblastine | 6 Months - 20 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease | NCT03516279 | Chronic Phase C... Minimal Residua... | Dasatinib Imatinib Mesyla... Laboratory Biom... Nilotinib Pembrolizumab | 18 Years - | Eastern Cooperative Oncology Group | |
| Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant | NCT00413270 | Chronic Myeloge... | nilotinib | 18 Years - | Novartis | |
| A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) | NCT04578847 | Chronic Myeloid... Chronic Myeloid... BCR-ABL Positiv... | Imatinib Nilotinib Dasatinib Bosutinib | 18 Years - | National Research Center for Hematology, Russia | |
| Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase | NCT00905593 | Chronic Myeloid... | Nilotinib | 18 Years - 60 Years | Novartis | |
| Nilotinib for First-line Newly Diagnosed CML-CP Patients | NCT03942094 | Chronic Myeloid... Nilotinib | Nilotinib | 18 Years - | Shenzhen Second People's Hospital | |
| A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | NCT00109707 | Chronic Myeloge... Acute Lymphobla... Hypereosinophil... Systemic Mastoc... | Nilotinib | 18 Years - | Novartis | |
| Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) | NCT01261429 | Pigmented Villo... | Tasigna | 18 Years - | Centre Leon Berard | |
| A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL | NCT00384228 | Chronic Myeloge... Acute Lymphobla... | Nilotinib | 20 Years - | Novartis | |
| Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy | NCT01456676 | Philadelphia Ch... | Nilotinib + LDE... | 18 Years - | Novartis | |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | NCT05286528 | Chronic Myeloid... | Bosutinib Imatinib Nilotinib Dasatinib Ponatinib | - | Pfizer | |
| Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas | NCT01140568 | Glioma | nilotinib | 18 Years - | University of California, San Diego | |
| Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) | NCT01261429 | Pigmented Villo... | Tasigna | 18 Years - | Centre Leon Berard | |
| Asciminib Roll-over Study | NCT04877522 | Chronic Myeloge... Leukemia, Myelo... | Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib | 18 Years - | Novartis | |
| Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance | NCT01819389 | Leukemia, Myelo... | Imatinib and Ni... | 18 Years - | Hospital Universitario Dr. Jose E. Gonzalez | |
| Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | NCT01275196 | Chronic Myeloid... | Nilotinib Imatinib | 18 Years - | Novartis | |
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. | NCT01743989 | Philadelphia Ch... | Nilotinib | 18 Years - | Novartis | |
| Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) | NCT00760877 | CHRONIC MYELOGE... | Nilotinib Imatinib | 18 Years - | Novartis | |
| Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST) | NCT01270893 | Gastrointestina... | Nilotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| Nilotinib Plus Pegylated Interferon-α2b in CML | NCT01866553 | Chronic Myeloid... | Nilotinib Pegylated inter... | 18 Years - | Amsterdam UMC, location VUmc | |
| Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults | NCT01884922 | Refractory Low-... Recurrent Low-g... | Nilotinib Vinblastine | 6 Months - 20 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase | NCT00481052 | Chronic Myeloid... | Nilotinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors | NCT01871311 | Colorectal Canc... Head and Neck C... | Nilotinib + Cet... | 18 Years - | Georgetown University | |
| Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | NCT01110668 | Gastrointestina... | Nilotinib | 18 Years - | Novartis | |
| Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib | NCT01475110 | Chronic Myeloid... | Imatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | NCT01275586 | Neurofibromatos... NF1 Neurofibromas | Tasigna | 18 Years - | Indiana University | |
| Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00905398 | Precursor B-Cel... Acute Lymphobla... | Nilotinib | 18 Years - 75 Years | Universidade Federal do Rio de Janeiro | |
| Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy | NCT02353728 | Chronic Myeloid... | Nilotinib | 18 Years - | Weill Medical College of Cornell University | |
| Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment | NCT01863745 | Gastrointestina... | nilotinib | 18 Years - | Novartis | |
| Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. | NCT01844765 | Philadelphia Po... | nilotinib | 1 Year - 17 Years | Novartis | |
| Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib | NCT02115386 | Philadelphia Po... | Nilotinib | 18 Years - | Novartis | |
| Nilotinib, for Patients With CML-CP or CML-AP | NCT04518644 | Chronic Myeloge... | Nilotinib | 18 Years - 99 Years | Novartis | |
| Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. | NCT01289028 | Gastrointestina... | Nilotinib | 18 Years - | Novartis | |
| Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor | NCT01207492 | Pigmented Villo... Diffuse-type Gi... Tenosynovial Gi... | nilotinib | 18 Years - | Dana-Farber Cancer Institute | |
| Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) | NCT00782834 | Gastrointestina... | Nilotinib | 18 Years - | Fox Chase Cancer Center | |
| Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia | NCT01805843 | Chronic Myeloid... | Echo, exercise ... | 18 Years - 95 Years | Medical University of Graz | |
| Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients | NCT03885830 | CML, Chronic Ph... CML (Chronic My... CML - Philadelp... Chronic Myeloid... Chronic Myeloid... | Bosutinib Dasatinib Imatinib Nilotinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults | NCT01884922 | Refractory Low-... Recurrent Low-g... | Nilotinib Vinblastine | 6 Months - 20 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults | NCT02611492 | Philadelphia Ch... | Nilotinib Methotrexate Aracytine (Ara ... Granulocyte Col... Depomedrol Dexamethasone Vincristine Imatinib 6 Mercaptopurin... | 18 Years - 59 Years | Assistance Publique - Hôpitaux de Paris | |
| Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib | NCT00644878 | Chronic Myeloge... | Nilotinib | 18 Years - | Novartis | |
| De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia | NCT01804985 | Chronic Myeloid... | Imatinib nilotinib dasatinib | 18 Years - | University of Liverpool | |
| Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response | NCT02326311 | Leukemia, Chron... | imatinib nilotinib dasatinib | 60 Years - | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | |
| Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations | NCT01131325 | CML Philadelphia Ch... Chronic Myeloge... | nilotinib | 18 Years - | Novartis | |
| Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) | NCT00129740 | Leukemia, Myelo... | Nilotinib | 16 Years - | M.D. Anderson Cancer Center | |
| Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia | NCT00769327 | Leukemia | imatinib mesyla... nilotinib cytogenetic ana... fluorescence in... microarray anal... mutation analys... polymerase chai... polymorphism an... laboratory biom... | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease | NCT03516279 | Chronic Phase C... Minimal Residua... | Dasatinib Imatinib Mesyla... Laboratory Biom... Nilotinib Pembrolizumab | 18 Years - | Eastern Cooperative Oncology Group | |
| 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients | NCT02917720 | Chronic Myeloid... | TKI discontinua... nilotinib | 18 Years - | European LeukemiaNet | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment | NCT01370980 | Cancer | 18 Years - | Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland | ||
| Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor | NCT01207492 | Pigmented Villo... Diffuse-type Gi... Tenosynovial Gi... | nilotinib | 18 Years - | Dana-Farber Cancer Institute | |
| Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia | NCT01914484 | Chronic Phase C... Accelerated Pha... Blastic Phase C... Philadelphia Po... Resistant to Ty... | Nilotinib Ruxolitinib | 18 Years - | University Health Network, Toronto | |
| Effect of 2nd Gen TKI in CML | NCT02222272 | Myeloid Leukemi... | 18 Years - | European Society for Blood and Marrow Transplantation | ||
| Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT01274351 | Chronic Myeloge... | Nilotinib | 18 Years - | Novartis | |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | NCT04971226 | Chronic Myeloid... | Imatinib Nilotinib Bosutinib Dasatinib Asciminib | 18 Years - | Novartis | |
| Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation | NCT04838041 | Chronic Phase C... | Asciminib 40 MG Asciminib 40 MG... Asciminib 80 MG... Imatinib Nilotinib Dasatinib | 18 Years - | Medical College of Wisconsin | |
| Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. | NCT02546674 | Chronic Myeloid... | Nilotinib | 18 Years - 120 Years | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
